文献速递慢性肾脏病血液净化与透析

C.E.R.A.在儿科血液透析合并肾性贫血患者中的维持疗效与长期安全性

Efficacy and Long-Term Safety of C.E.R.A. Maintenance in Pediatric Hemodialysis Patients with Anemia of CKD.
PubMed 文献 · Clin J Am Soc Nephrol · 2017-11-02

这项开放标签、多中心研究纳入64例6-17岁接受血液透析的慢性肾脏病贫血患者,确定从促红细胞生成素刺激剂转换为C.E.R.A.的转换因子,并评估其疗效与长期安全性。结果显示,按该转换因子每4周给药可维持血红蛋白在目标范围,安全性与成人已知特征一致。

要点

  • 确定转换因子:每4周4微克C.E.R.A.对应每周125 IU epoetin alfa/beta或0.55微克darbepoetin。
  • 转换后81%患者血红蛋白维持在10.0-12.0 g/dl,75%维持在基线1.0 g/dl以内。
  • 长期安全性未发现新信号,与成人研究相似。

核心结论

  • 使用确定的转换因子,每4周一次C.E.R.A.可有效维持儿科血液透析合并稳定肾性贫血患者的血红蛋白水平。
  • 安全性与成人已知的C.E.R.A.安全性特征一致,未检测到新信号。

研究设计与样本

  • 开放标签、多中心研究,纳入64例6-17岁接受血液透析的慢性肾脏病贫血患者。
  • 患者接受每4周一次C.E.R.A.,起始剂量由既往每周epoetin alfa/beta或darbepoetin剂量决定。
  • 经过16周剂量滴定和4周评估期后,血红蛋白稳定的患者可进入为期1年的可选安全性延长期。

主要发现

  • 从基线到评估期的血红蛋白调整后平均变化为-0.09 g/dl(95%CI -0.45至0.26)。
  • 81%的患者血红蛋白维持在10.0-12.0 g/dl,75%维持在基线1.0 g/dl以内。
  • 结果在年龄组(6-11岁和12-17岁)和既往ESA类型间一致。
  • 末次观察时70%患者血红蛋白在10.0-12.0 g/dl,62%在基线±1.0 g/dl以内。

关键数值与推荐

  • 转换因子:每4周4微克C.E.R.A.对应每周125 IU epoetin alfa/beta或0.55微克darbepoetin。

临床怎么用

  • 儿科血液透析合并肾性贫血患者从epoetin alfa/beta或darbepoetin转换为C.E.R.A.时,可按每4周4微克对应每周125 IU epoetin alfa/beta或0.55微克darbepoetin的转换因子确定起始剂量。
  • 转换后应监测血红蛋白以维持在目标范围,并根据需要调整剂量。

局限性

  • 开放标签设计,无对照组。
  • 样本量较小(64例),安全性延长期完成率较低(17例完成73周)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: The study was conducted to identify a conversion factor for switching from previous erythropoiesis-stimulating agents (ESAs) to continuous erythropoietin receptor activator-methoxy polyethylene glycol-epoetin beta (C.E.R.A.) and to document the efficacy and long-term safety of C.E.R.A. in pediatric patients with anemia of CKD undergoing hemodialysis. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: In this open-label, multicenter study, patients aged 6-17 years, with stable chronic anemia of CKD, undergoing hemodialysis received C.E.R.A. every 4 weeks, at a starting dose determined by previous weekly epoetin alfa/beta or darbepoetin dosing. After a 16-week dose-titration and a 4-week evaluation period, patients with stable hemoglobin could enter a 1-year optional safety extension. RESULTS: A total of 64 patients were enrolled. A conversion factor (4 µg every 4 weeks for each weekly dose of 125 IU epoetin alfa/beta or 0.55 µg darbepoetin) was identified that allowed patients to maintain hemoglobin within target levels on switching to C.E.R.A. from another ESA. Using this conversion factor, the adjusted mean change in hemoglobin from baseline to evaluation was -0.09 g/dl (95% confidence interval, -0.45 to 0.26); 81% of patients maintained hemoglobin within 10.0-12.0 g/dl and 75% maintained hemoglobin within 1.0 g/dl of baseline. Results were consistent across age groups (6-11 and 12-17 years) and previous ESA. Thirty-seven patients entered the safety extension period and 17 completed 73 weeks of treatment. Most withdrawals were for kidney transplantation. A total of 70% of patients had hemoglobin within 10.0-12.0 g/dl at last observation, and 62% were within ±1.0 g/dl of baseline. Safety was similar to studies in adult patients, with no new signal detected. CONCLUSIONS: Using a defined conversion factor, 4-weekly C.E.R.A. was efficacious in maintaining hemoglobin levels in pediatric patients with stable anemia of CKD undergoing hemodialysis, switching from maintenance treatment with epoetin alfa/beta or darbepoetin. Safety was consistent with the known C.E.R.A. safety profile in adults.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Fischbach M, Wühl E, Reigner SCM, et al. Efficacy and Long-Term Safety of C.E.R.A. Maintenance in Pediatric Hemodialysis Patients with Anemia of CKD. Clin J Am Soc Nephrol. 2017. PMID: 29097481. doi:10.2215/CJN.03570417

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。